Silo Pharma Inc. (NASDAQ: SILO) has received a Notice of Allowance from the United States Patent and Trademark Office for a patent application covering SPC-15, its lead intranasal therapeutic for post-traumatic stress disorder. The allowance marks a critical step in securing U.S. intellectual property rights for the company's innovative approach to preventing stress-induced behavioral responses.
The patent, titled “Compositions and Methods for the Prevention of Stress-Induced Fear, Depressive-Like and Anxiety-Like Behavior,” encompasses both composition and method claims. These claims cover Silo's proprietary formulation and its use in preventing or delaying stress-induced fear, depressive-like and anxiety-like behaviors. A corresponding patent was issued by the Japan Patent Office earlier this year, indicating global recognition of the technology's novelty.
A Notice of Allowance signifies that the USPTO has completed its examination and determined that the application meets all requirements for patentability. The patent is expected to be granted shortly. This development is important because it provides Silo Pharma with exclusive rights to SPC-15 in the United States, a key market for pharmaceutical innovation. Such protection is vital for attracting investment and partnerships needed to advance the therapeutic through clinical trials and eventual commercialization.
PTSD affects millions of people worldwide, and current treatment options often have limitations. SPC-15's intranasal delivery offers a potentially more convenient and effective method for managing the disorder. By targeting stress-induced fear and anxiety, SPC-15 could address a significant unmet need in mental health care. The patent allowance not only validates the scientific foundation of SPC-15 but also enhances Silo's competitive position in the growing neuropsychiatric drug market.
Silo Pharma's broader portfolio includes other developmental programs, such as SP-26 for fibromyalgia and chronic pain, and preclinical assets for Alzheimer's disease and multiple sclerosis. The company collaborates with leading universities and laboratories to drive its research forward. The addition of this U.S. patent to Silo's intellectual property portfolio underscores its commitment to developing therapies for underserved conditions.
For investors, the patent allowance reduces regulatory risk and increases the potential for future revenue streams. It also signals progress in Silo's pipeline, which could lead to licensing deals or collaborations with larger pharmaceutical companies. The news is particularly relevant given the high prevalence of PTSD and the limited efficacy of existing treatments. Silo's focus on stress-induced psychiatric disorders positions it in a niche with substantial growth potential.
To view the full press release, visit https://ibn.fm/Hh4Z6. For more information about Silo Pharma, visit silopharma.com. The latest news and updates relating to SILO are available in the company's newsroom at https://ibn.fm/SILO.
